KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cadre Holdings (CDRE) Asset Writedowns and Impairment (2020 - 2025)

Historic Asset Writedowns and Impairment for Cadre Holdings (CDRE) over the last 6 years, with Q3 2025 value amounting to -$230000.0.

  • Cadre Holdings' Asset Writedowns and Impairment fell 181666.67% to -$230000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$183000.0, marking a year-over-year decrease of 12328.24%. This contributed to the annual value of $764000.0 for FY2024, which is 105757.58% up from last year.
  • Per Cadre Holdings' latest filing, its Asset Writedowns and Impairment stood at -$230000.0 for Q3 2025, which was down 181666.67% from $57000.0 recorded in Q2 2025.
  • Cadre Holdings' Asset Writedowns and Impairment's 5-year high stood at $480000.0 during Q1 2024, with a 5-year trough of -$230000.0 in Q3 2025.
  • In the last 5 years, Cadre Holdings' Asset Writedowns and Impairment had a median value of $40000.0 in 2023 and averaged $45736.8.
  • In the last 5 years, Cadre Holdings' Asset Writedowns and Impairment skyrocketed by 110000.0% in 2024 and then crashed by 181666.67% in 2025.
  • Quarter analysis of 5 years shows Cadre Holdings' Asset Writedowns and Impairment stood at $66000.0 in 2021, then soared by 160.61% to $172000.0 in 2022, then tumbled by 83.14% to $29000.0 in 2023, then tumbled by 75.86% to $7000.0 in 2024, then crashed by 3385.71% to -$230000.0 in 2025.
  • Its Asset Writedowns and Impairment stands at -$230000.0 for Q3 2025, versus $57000.0 for Q2 2025 and -$17000.0 for Q1 2025.